MDXG Logo

MiMedx Group, Inc. (MDXG) Stock Forecast & Price Prediction

Live MDXG Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$8.40

+0.12 (1.45%)

12 Month Price Forecast For MDXG

$8.40
Current Price
$1.23B
Market Cap
5 Ratings
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to MDXG Price Forecasts

+90.5%
To High Target of $16.00
+54.8%
To Median Target of $13.00
+42.9%
To Low Target of $12.00

MDXG Price Momentum

+1.1%
1 Week Change
-4.8%
1 Month Change
+1.9%
1 Year Change
-12.7%
Year-to-Date Change
-17.2%
From 52W High of $10.14
+53.6%
From 52W Low of $5.47

๐Ÿค” Considering MiMedx (MDXG)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 5:56 PM UTC

MDXG Analyst Ratings & Price Targets

Based on our analysis of 6 Wall Street analysts, MDXG has a bullish consensus with a median price target of $13.00 (ranging from $12.00 to $16.00). Currently trading at $8.40, the median forecast implies a 54.8% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.

Conversely, the most conservative target is provided by Chase Knickerbocker at Craig-Hallum, suggesting a 42.9% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

MDXG Analyst Consensus

5
Buy
0
Hold
0
Sell

MDXG Price Target Range

Low
$12.00
Average
$13.00
High
$16.00
Current: $8.40

Latest MDXG Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for MDXG.

Date Firm Analyst Rating Change Price Target
Aug 1, 2024 Cantor Fitzgerald Ross Osborn Overweight Reiterates $11.00
Aug 1, 2024 Craig-Hallum Chase Knickerbocker Buy Maintains $12.00
Jul 2, 2024 Cantor Fitzgerald Ross Osborn Overweight Initiates $11.00
May 1, 2024 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $11.00
Mar 7, 2024 Lake Street Brooks O'Neil Buy Initiates $12.00
Mar 1, 2024 Mizuho Anthony Petrone Buy Maintains $14.00
Oct 31, 2023 Mizuho Anthony Petrone Buy Maintains $12.00
Oct 27, 2023 Craig-Hallum Chase Knickerbocker Buy Initiates $12.00
Aug 2, 2023 HC Wainwright & Co. Swayampakula Ramakanth Buy Maintains $11.00
Aug 2, 2023 Mizuho Anthony Petrone Buy Maintains $12.00
Jun 21, 2023 HC Wainwright & Co. Swayampakula Ramakanth Buy Maintains $8.00
May 3, 2023 HC Wainwright & Co. Swayampakula Ramakanth Buy Maintains $9.50
Mar 2, 2023 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $8.00
Oct 13, 2022 Mizuho Anthony Petrone Buy Initiates $7.00
Sep 7, 2022 HC Wainwright & Co. Swayampakula Ramakanth Buy Maintains $8.00
Sep 14, 2021 HC Wainwright & Co. Swayampakula Ramakanth Buy Maintains $8.50
Jul 26, 2021 Northland Capital Markets Outperform Initiates $0.00
Mar 19, 2021 HC Wainwright & Co. Buy Initiates $0.00
Feb 26, 2018 Lake Street Hold Downgrade $0.00
Feb 20, 2018 Needham Hold Downgrade $0.00

Stocks Similar to MiMedx Group, Inc.

The following stocks are similar to MiMedx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

MiMedx Group, Inc. (MDXG) Financial Data

MiMedx Group, Inc. has a market capitalization of $1.23B with a P/E ratio of 14.7x. The company generates $342.80M in trailing twelve-month revenue with a 25.8% profit margin.

Revenue growth is +2.9% quarter-over-quarter, while maintaining an operating margin of +13.6% and return on equity of +62.5%.

Valuation Metrics

Market Cap $1.23B
Enterprise Value $1.16B
P/E Ratio 14.7x
PEG Ratio 27.1x
Price/Sales 3.6x

Growth & Margins

Revenue Growth (YoY) +2.9%
Gross Margin +81.8%
Operating Margin +13.6%
Net Margin +25.8%
EPS Growth -5.1%

Financial Health

Cash/Price Ratio +7.2%
Current Ratio 4.1x
Debt/Equity 10.5x
ROE +62.5%
ROA +18.4%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

MiMedx Group, Inc. logo

MiMedx Group, Inc. (MDXG) Company Overview

About MiMedx Group, Inc.

What They Do

Develops and distributes placental tissue allografts.

Business Model

The company processes human placental tissues using its proprietary PURION process, creating allografts that retain biological properties. It generates revenue by selling products like EpiFix and AmnioFix through a direct sales force, independent agents, and distributors, primarily in the U.S.

Additional Information

Founded in 2006 and headquartered in Marietta, Georgia, MiMedx offers products targeting wound care, burns, and surgical recovery, addressing critical healthcare needs.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

895

CEO

Mr. Joseph H. Capper

Country

United States

IPO Year

2008

MiMedx Group, Inc. (MDXG) Latest News & Analysis

MDXG stock latest news image
Quick Summary

MiMedx (MDXG) is highlighted as a potential choice for short-term investors, having passed a trading strategy screen for fundamentally sound stocks.

Why It Matters

MiMedx's recent performance and solid fundamentals suggest potential for short-term gains, making it an attractive option for traders seeking quick profits.

Source: Zacks Investment Research
Market Sentiment: Positive
MDXG stock latest news image
Quick Summary

MiMedx (MDXG) is identified as a strong candidate for investors, having passed the "Recent Price Strength" screening, indicating potential for continued upward momentum.

Why It Matters

MiMedx (MDXG) shows strong recent performance, indicating momentum and potential for continued growth, attracting investors seeking upward-trending stocks.

Source: Zacks Investment Research
Market Sentiment: Positive
MDXG stock latest news image
Quick Summary

Analysts' price targets for MiMedx (MDXG) suggest a 37.1% upside, supported by strong agreement in raised earnings estimates among analysts.

Why It Matters

Analysts' price targets suggesting a 37.1% upside, along with raised earnings estimates, signal potential growth for MiMedx (MDXG), attracting investor interest.

Source: Zacks Investment Research
Market Sentiment: Positive
MDXG stock latest news image
Quick Summary

MiMedx Group, Inc. announced that over 200 unproven skin substitutes will no longer be covered under revised Local Coverage Determinations, favoring clinically effective products.

Why It Matters

The exclusion of unproven skin substitutes from coverage may boost MiMedx's sales of clinically effective products, potentially enhancing revenue and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
MDXG stock latest news image
Quick Summary

MiMedx (MDXG) is identified as a potential option for short-term investors, having passed a trading strategy screen focused on fundamentally sound stocks.

Why It Matters

MiMedx's recent price trend and strong fundamentals signal potential short-term gains, attracting traders seeking quick investment opportunities.

Source: Zacks Investment Research
Market Sentiment: Positive
MDXG stock latest news image
Quick Summary

MiMedx (MDXG) has a consensus price target suggesting a 77.9% upside. Recent upward revisions in earnings estimates may indicate potential near-term growth.

Why It Matters

A 77.9% upside target and positive earnings estimate revisions suggest MiMedx (MDXG) may experience significant short-term price appreciation, attracting investor interest.

Source: Zacks Investment Research
Market Sentiment: Positive

Frequently Asked Questions About MDXG Stock

What is MiMedx Group, Inc.'s (MDXG) stock forecast for 2025?

Based on our analysis of 6 Wall Street analysts, MiMedx Group, Inc. (MDXG) has a median price target of $13.00. The highest price target is $16.00 and the lowest is $12.00.

Is MDXG stock a good investment in 2025?

According to current analyst ratings, MDXG has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.40. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for MDXG stock?

Wall Street analysts predict MDXG stock could reach $13.00 in the next 12 months. This represents a 54.8% increase from the current price of $8.40. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is MiMedx Group, Inc.'s business model?

The company processes human placental tissues using its proprietary PURION process, creating allografts that retain biological properties. It generates revenue by selling products like EpiFix and AmnioFix through a direct sales force, independent agents, and distributors, primarily in the U.S.

What is the highest forecasted price for MDXG MiMedx Group, Inc.?

The highest price target for MDXG is $16.00 from at , which represents a 90.5% increase from the current price of $8.40.

What is the lowest forecasted price for MDXG MiMedx Group, Inc.?

The lowest price target for MDXG is $12.00 from Chase Knickerbocker at Craig-Hallum, which represents a 42.9% increase from the current price of $8.40.

What is the overall MDXG consensus from analysts for MiMedx Group, Inc.?

The overall analyst consensus for MDXG is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.

How accurate are MDXG stock price projections?

Stock price projections, including those for MiMedx Group, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.